Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 11 articles:
HTML format



Single Articles


    October 2022
  1. YOON S, Shin SJ, Kim HC, Kim YS, et al
    Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure.
    Eur J Cancer. 2022;174:81-89.
    PubMed     Abstract available


    June 2022
  2. LIU Z, Jin K, Zeng H, Shao F, et al
    B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer.
    Eur J Cancer. 2022;171:133-142.
    PubMed     Abstract available


    May 2022
  3. KLUMPER N, Sikic D, Saal J, Buttner T, et al
    C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.
    Eur J Cancer. 2022;167:13-22.
    PubMed     Abstract available


    March 2022
  4. SONPAVDE GP, Sternberg CN, Loriot Y, Marabelle A, et al
    Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.
    Eur J Cancer. 2022;163:55-65.
    PubMed     Abstract available


    November 2021
  5. SEETHAPATHY H, Street S, Strohbehn I, Lee M, et al
    Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors.
    Eur J Cancer. 2021;157:50-58.
    PubMed     Abstract available


    July 2021
  6. MORI K, Pradere B, Moschini M, Mostafaei H, et al
    First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Eur J Cancer. 2021;151:35-48.
    PubMed     Abstract available


  7. BOUDIN L, Patient M, Romeo E, Blade JS, et al
    Lurbinectedin for metastatic small-cell bladder carcinoma.
    Eur J Cancer. 2021;151:1-2.
    PubMed    


    May 2021
  8. ROUANNE M, Arpaia N, Marabelle A
    CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer.
    Eur J Cancer. 2021 May 7. pii: S0959-8049(21)00222.
    PubMed    


    March 2021
  9. GROENEVELD CS, Fontugne J, Cabel L, Bernard-Pierrot I, et al
    Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
    Eur J Cancer. 2021;148:181-189.
    PubMed     Abstract available


  10. BAART VM, van der Horst G, Deken MM, Bhairosingh SS, et al
    A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma.
    Eur J Cancer. 2021;146:11-20.
    PubMed     Abstract available


    May 2020
  11. MATSUMOTO S, Kijima T, Matsuoka Y, Yamamoto M, et al
    A case of recurrent thrombocytopenia involving divergent immune-related mechanisms associated with pembrolizumab.
    Eur J Cancer. 2020;131:104-107.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: